No active infections requiring systemic antibiotic treatment (oral antibiotics are acceptable at the discretion of the treating physician)
Active systemic infection requiring parenteral antibiotic therapy; all prior infections must have resolved following optimal therapy
Active infection requiring systemic antibiotic therapy.
Active infection requiring systemic antibiotic therapy
Active systemic infection requiring parenteral antibiotic therapy. All prior infections must have resolved following optimal therapy
Active infection requiring systemic antibiotic therapy.
Subjects with active infection requiring antibiotic therapy
Active infection requiring systemic antibiotic therapy
Active infection requiring systemic antibiotic therapy.
Must be free of systemic infection; subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection; subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment
Has an active infection requiring systemic antibiotic therapy at time of enrollment\r\n* Treatment with antibiotic prophylaxis for indwelling biliary stent(s) or peri-procedural antibiotics for uncomplicated biliary stent exchanges is allowed and not an exclusion
Active infection requiring systemic antibiotic therapy
Must be free of systemic infection; subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection; subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment
Active infection requiring systemic antibiotic therapy.
EXCLUSION - PARTICIPANT: Active infection requiring systemic antibiotic therapy. Participants requiring systemic antibiotics for infection must have completed therapy before treatment is initiated.
Must be free of systemic infection:\r\n* Subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection\r\n* Subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment
Active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy
Known infection requiring the systemic use of, for example, an antibiotic or antiviral agent
Current active infection requiring systemic antibiotic or antifungal therapy
Infection requiring intravenous antibiotic use within one week of enrollment.
Subjects must not have a known active infection requiring intravenous antibiotic therapy
Active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy
DONOR: Evidence of infection not responding to antibiotic therapy
Active infection requiring intravenous (IV) antibiotic usage within the last week prior to study treatment
Has an active infection requiring intravenous antibiotic therapy
Any antibiotic therapy or evidence of infection within 1 week of registration
Active infection requiring intravenous (IV) antibiotic usage within the last week prior to the dosimetry portion of the study
Infection requiring current intravenous antibiotic therapy; the PI will serve as the final arbiter regarding eligibility
Evidence of active infection requiring antibiotic therapy ? 14 days prior to the first dose of PRTX- 100
Must be free of systemic infection; subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection; subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment
Patients with ongoing use of prophylactic antibiotics are eligible as long as there is no evidence of active infection and the antibiotic is not included on the list of prohibited medications
Patients who have evidence of active infection that requires antibiotic therapy; patients must have been off antibiotic treatment for at least 3 weeks prior to initiating treatment and must be confirmed to be clear of the infection; if patient develops an infection requiring antibiotic treatment while on the treatment portion of the study patients will be treated for the active infection with antibiotics and will resume vaccine treatment when the infection is healed
Has an active infection requiring systemic therapy NOTE: Antibiotic therapy must have been completed a minimum of 3 days prior to start of study treatment;
Current use of antibiotic rinses or troches
Active systemic infection requiring parenteral antibiotic therapy
Has uncontrolled active infection of any kind. (Patients with infections controlled by active antibiotic treatment are eligible).
Infection requiring intravenous antibiotic use within 1 week.
Concurrent serious infections (i.e., requiring an intravenous antibiotic)
Active infection requiring IV antibiotic usage within the last week prior to study treatment
Infection requiring intravenous antibiotic use within 1 week.
Requires hospitalization for IV empiric antibiotic therapy
Has an active infection requiring systemic therapy; prior to dosing with REGN2810 the subject must be at least 5 half-lives from their last dose of antibiotic
Evidence of ongoing or active infection requiring antibiotic therapy
Active infection requiring systemic antibiotic therapy.
Acute/chronic infections, open wounds, or any active infection requiring intravenous antibiotic therapy =< 12 weeks prior to registration
Any active infection requiring antibiotic therapy within 2 weeks of study day 1.
No active systemic infection requiring parenteral antibiotic therapy
Active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy
An infection requiring antibiotic treatment within seven days of starting study treatment (day -1)
Active infection requiring systemic antibiotic therapy.
Active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy
No active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy
Any infection requiring antibiotic or anti-viral treatment within 4 weeks of screening
Any infection requiring parenteral antibiotic therapy or causing fever (temperature > 100.5°F or 38.1°C) within 1 week prior to registration
Subjects with clinically serious infections requiring ongoing antibiotic therapy
Patients with infections requiring intravenous (IV) antibiotic/antiviral therapy are not eligible for entry onto the study; patients on prophylactic antibiotics or antivirals are acceptable.
Active infection requiring systemic antibiotic therapy
Any antibiotic therapy or evidence of infection within 1 week of registration
Must be free of systemic infection; subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection; subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment
Patients with active infection requiring systemic therapy or who are dependent on or currently receiving antibiotics that cannot be discontinued before dosing; (Note: subjects who discontinue an antibiotic prior to dosing must wait at least 5 half-lives after the last dose of antibiotic before receiving any ADXS11-001 infusion)
Current infections requiring antibiotic therapy.
Requires hospitalization for intravenous (IV) empiric antibiotic therapy
Concurrent serious infection requiring parenteral antibiotic therapy.
Patients requiring intravenous (IV) antiviral or IV antibiotic treatment for ongoing infections
Patients requiring IV antiviral or IV antibiotic treatment for ongoing infections
Known active infection requiring antibiotic treatment before the start of treatment (day 0)
Concurrent serious infections requiring parenteral antibiotic therapy.
Active systemic infection requiring systemic antibiotic treatment within 72 hours prior to first dose of study treatment
Receiving antibiotic therapy within 14 days before the first dose of study treatment
any infection requiring antibiotic, anticoagulant, or antiplatelet agents within the past 4 weeks
Active infection requiring antibiotic treatment
Active infection requiring antibiotic therapy
Any evidence of serious active, uncontrolled infection (i.e., requiring an IV antibiotic or antiviral agent)
Be receiving quinolone antibiotic therapy
Planned continuous antibiotic treatment during RT
Patients with ongoing use of prophylactic antibiotics are eligible as long as there is no evidence of active infection and the antibiotic is not included on the list of prohibited medications
Patients undergoing active antibiotic therapy
Planned continuous antibiotic treatment during RT
Require antibiotic therapy prior to oral cleaning
Patient is receiving antibiotic therapy for an active infection
Known active infection requiring antibiotic treatment
Active infection requiring systemic IV antibiotic therapy
Patients with ongoing use of prophylactic antibiotics are eligible as long as there is no evidence of active infection and the antibiotic is not a prohibited medication
have an active infection requiring antibiotic therapy, or concomitant malignancies
